Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer
JAMA Network Open · 11.05.2026 · 9 (5) · e2612133
DOI: 10.1001/jamanetworkopen.2026.12133 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 11.05.2026. Verfasst von Kristina L Tatum und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social and Behavioral Sciences, School of Public Health, Virginia Commonwealth University, Richmond. Hauptthemen laut MEDLINE: Breast Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Neoplasm Recurrence, Local, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Patients with breast cancer (BC) with comorbid obesity or type 2 diabetes (T2D) experience poorer survival. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved to treat these comorbidities; however, their associations with BC survival and recurrence remain unclear.
Objective
To evaluate the association between GLP-1 RA use and 10-year all-cause mortality and recurrence-free survival (RFS) over the 10-year follow-up period, as well as 5- and 10-year all-cause mortality and RFS probabilities among patients with BC. Design, Setting, and Participants This retrospective cohort study used TriNetX US Collaborative Network data from women (≥18 years) with BC from 68 health care organizations who received a diagnosis between April 1, 2006, and April 1, 2023. Propensity score matching balanced characteristics. Data were analyzed between September 16 and October 3, 2025. Exposures GLP-1 RA use (≥2 prescriptions) during the 6 months before and any time after the index diagnosis; nonuse (0 entries). Main Outcomes and Measures The primary outcome was all-cause mortality, and the secondary outcome was RFS. Cox proportional hazards regression model–estimated hazard ratios (HRs) were restricted to 10 years. Kaplan-Meier estimators were used to calculate 5- and 10-year all-cause mortality and RFS probabilities. Prespecified subgroup (postmenopausal) and landmark (6- and 12-month) analyses were conducted.
Results
The study comprised 841 831 eligible patients with BC (mean [SD] age, 69.1 [12.2] years). After exclusions and 1:1 propensity score matching, 3 cohorts were identified: 1610 patients for GLP-1 RA use vs nonuse (patients with obesity [body mass index ≥30]), 2323 patients for GLP-1 RA use vs insulin or metformin (patients with T2D), and 4052 patients for GLP-1 RA use vs sodium-glucose cotransporter 2 inhibitors (patients with T2D). Among patients with obesity, GLP-1 RAs were associated with lower hazard of all-cause mortality (HR, 0.35; 95% CI, 0.21-0.58; P < .001) and RFS (HR, 0.44; 95% CI, 0.30-0.64; P < .001) over a 10-year follow-up period. Among patients with T2D, GLP-1 RAs vs insulin or metformin were associated with lower hazard of all-cause mortality (HR, 0.09; 95% CI, 0.06-0.15; P < .001) and RFS (HR, 0.33; 95% CI, 0.21-0.50; P < .001). No significant differences were observed between GLP-1 RA and sodium-glucose cotransporter 2 inhibitor groups. Subgroup and landmark analyses yielded similar findings. Conclusions and Relevance In this cohort study of patients with BC, findings suggested a potential association between GLP-1 RA use and improved outcomes among patients with BC who have obesity and related metabolic conditions. These findings support further evaluation of GLP-1 RA therapy in randomized clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Social and Behavioral Sciences, School of Public Health, Virginia Commonwealth University, Richmond.
- Department of Health Policy, School of Public Health, Virginia Commonwealth University, Richmond.
- Virginia State University, Petersburg.
- TriNetX LCC, Cambridge, Massachusetts.
- Division of Hematology, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond.
- Department of Public Health Sciences, University of Virginia, Charlottesville.
Förderung
- NCI NIH HHS
Zitieren
APA
Tatum, K. L., Dahman, B., Stevenson, A., Williford, S. E., Cassel, J. B., Zhao, H., Shen, J., McGuire, K. P., Diala, O., Oladimeji, R., Hundley, W. G., & Fuemmeler, B. F. (2026). Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. JAMA Network Open, 9(5), e2612133. https://doi.org/10.1001/jamanetworkopen.2026.12133
Vancouver
Tatum KL, Dahman B, Stevenson A, Williford SE, Cassel JB, Zhao H, et al. Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133
BibTeX
@article{Tatum2026,
author = {Tatum, Kristina L and Dahman, Bassam and Stevenson, Aniyah and Williford, Sarah E and Cassel, J Brian and Zhao, Hua and Shen, Jie and McGuire, Kandace P and Diala, Obinna and Oladimeji, Racheal and Hundley, W Greg and Fuemmeler, Bernard F},
title = {Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {5},
pages = {e2612133},
doi = {10.1001/jamanetworkopen.2026.12133}
}
EUVIMED